India
· Delayed Price · Currency is INR Marksans Pharma Statistics
Total Valuation
Marksans Pharma has a market cap or net worth of INR 119.22 billion. The enterprise value is 114.87 billion.
| Market Cap | 119.22B |
| Enterprise Value | 114.87B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | Sep 17, 2024 |
Share Statistics
Marksans Pharma has 453.16 million shares outstanding. The number of shares has increased by 6.46% in one year.
| Shares Outstanding | 453.16M |
| Shares Change (YoY) | +6.46% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 43.87% |
| Owned by Institutions (%) | 10.57% |
| Float | 204.31M |
Valuation Ratios
The trailing PE ratio is 35.75 and the forward PE ratio is 30.83. Marksans Pharma's PEG ratio is 1.28.
| PE Ratio | 35.75 |
| Forward PE | 30.83 |
| PS Ratio | 5.26 |
| PB Ratio | 5.77 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.28 |
Enterprise Valuation
| EV / Earnings | 34.41 |
| EV / Sales | 5.06 |
| EV / EBITDA | 23.51 |
| EV / EBIT | 28.43 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 11.70 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | n/a |
| Interest Coverage | 32.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 11.97% |
| Revenue Per Employee | 19.88M |
| Profits Per Employee | 2.93M |
| Employee Count | 1,141 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +143.38% in the last 52 weeks. The beta is 1.63, so Marksans Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | +143.38% |
| 50-Day Moving Average | 204.45 |
| 200-Day Moving Average | 169.39 |
| Relative Strength Index (RSI) | 75.89 |
| Average Volume (20 Days) | 4,797,486 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marksans Pharma had revenue of INR 22.68 billion and earned 3.34 billion in profits. Earnings per share was 7.36.
| Revenue | 22.68B |
| Gross Profit | 12.11B |
| Operating Income | 4.04B |
| Pretax Income | 4.47B |
| Net Income | 3.34B |
| EBITDA | 4.89B |
| EBIT | 4.04B |
| Earnings Per Share (EPS) | 7.36 |
Balance Sheet
The company has 7.01 billion in cash and 2.44 billion in debt, giving a net cash position of 4.57 billion or 10.07 per share.
| Cash & Cash Equivalents | 7.01B |
| Total Debt | 2.44B |
| Net Cash | 4.57B |
| Net Cash Per Share | 10.07 |
| Equity (Book Value) | 20.86B |
| Book Value Per Share | 45.63 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 53.39%, with operating and profit margins of 17.81% and 14.72%.
| Gross Margin | 53.39% |
| Operating Margin | 17.81% |
| Pretax Margin | 19.70% |
| Profit Margin | 14.72% |
| EBITDA Margin | 21.55% |
| EBIT Margin | 17.81% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.23%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 0.23% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -6.46% |
| Shareholder Yield | -6.23% |
| Earnings Yield | 2.80% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |